Topical nepafenac for treatment of exudative age-related macular degeneration

Acta Ophthalmologica

Volumn 88, Issue 2, 2010, Pages

  Libondi, Teodosio ^a   Jonas, Jost B ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEPAFENAC;

AGED; CASE REPORT; HUMAN; LETTER; PRIORITY JOURNAL; RETINA EXUDATE; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULAR DEGENERATION; OPHTHALMIC SOLUTIONS; PHENYLACETATES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 77649211470     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01491.x     Document Type: Letter

References (14)

1. Algvere PV, Steén B, Seregard S Kvanta A (2008 A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 86 : 482 489.
2. Amrite AC Kompella UB (2008 Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther 324 : 749 758.
3. Frimpong-Boateng A, Bunse A, Rüfer F Roider J (2008 Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol [Epub ahead of print].
4. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P Billson F (2003 A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121 : 667 673.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004 Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 : 2805 2816.
6. Jonas JB (2005 Intravitreal triamcinolone acetonide: an experimental clinical procedure. Acta Ophthalmol 83 : 526 527.
7. Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Sauder G Spandau UH (2007 Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol 85 : 563 565.
8. Jonas JB, Spandau UH Schlichtenbrede F (2008 Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 22 : 590 591.
9. Kern TS, Miller CM, Du Y et al. (2007 Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 56 : 373 379.
10. Rosenfeld PJ, Moshfeghi AA Puliafito CA (2005 Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 : 331 335.
11. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY MARINA Study Group (2006 Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 : 1419 1431.
12. Schmidt-Erfurth UM, Richard G, Augustin A et al. (2007 Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol 85 : 486 494. (Pubitemid 47163109)
13. Takahashi K, Saishin Y, Saishin Y et al. (2003 Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 44 : 409 415.
14. Virgili G, Do DV, Bressler NM Menchini U (2007 New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Acta Ophthalmol 85 : 6 20.